tiprankstipranks
Trending News
More News >
Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
India Market
Advertisement

Aurobindo Pharma Ltd (AUROPHARMA) AI Stock Analysis

Compare
3 Followers

Top Page

IN:AUROPHARMA

Aurobindo Pharma Ltd

(AUROPHARMA)

Select Model
Select Model
Select Model
Outperform 76 (OpenAI - 4o)
Rating:76Outperform
Price Target:
₹1,265.00
▲(13.69% Upside)
Aurobindo Pharma Ltd's strong financial performance is the most significant factor, driven by robust revenue growth and improved profitability. Technical analysis indicates neutral momentum, with a slight bullish trend. Valuation is fair, though the low dividend yield may deter income-focused investors. The absence of earnings call data and corporate events does not impact the score.

Aurobindo Pharma Ltd (AUROPHARMA) vs. iShares MSCI India ETF (INDA)

Aurobindo Pharma Ltd Business Overview & Revenue Model

Company DescriptionAurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
How the Company Makes MoneyAurobindo Pharma generates revenue primarily through the sale of generic pharmaceuticals, which constitutes a significant portion of its earnings. The company has a diversified portfolio that includes a wide range of formulations and APIs, allowing it to cater to various therapeutic areas. Key revenue streams include the sale of generic drugs in the United States, Europe, and emerging markets, as well as the production of APIs for other pharmaceutical companies. The company's robust research and development capabilities enable it to create a continuous pipeline of new products, contributing to its competitive edge. Additionally, strategic partnerships and collaborations with other pharmaceutical companies enhance its market reach and facilitate entry into new markets, further bolstering its revenue. Aurobindo's focus on cost-effective manufacturing processes and economies of scale also plays a crucial role in its profitability.

Aurobindo Pharma Ltd Financial Statement Overview

Summary
Aurobindo Pharma Ltd exhibits a strong financial profile characterized by impressive revenue growth and improved profitability margins. The balance sheet is robust with low leverage and a strong equity base, though there is room to enhance return on equity. Cash flow performance has recovered well, underscoring effective cash management. The company is well-positioned for future growth, though maintaining operational efficiency will be crucial.
Income Statement
85
Very Positive
Aurobindo Pharma has demonstrated strong revenue growth with a significant increase from ₹290,018.7 million to ₹317,237.3 million, indicating robust sales momentum. Gross profit margin has improved to 58.9%, and net profit margin has steadily grown to 11%. This highlights the company's enhanced profitability. However, EBITDA margin has decreased slightly, suggesting some pressure on operating efficiency.
Balance Sheet
78
Positive
The balance sheet reflects a solid financial position with a low debt-to-equity ratio of 0.25, showcasing effective leverage management. The equity ratio stands at 65.6%, indicating a strong equity base relative to total assets. Return on equity is satisfactory at 10.7%, though it suggests potential room for improvement in generating shareholder returns.
Cash Flow
82
Very Positive
The cash flow statement reveals a strong recovery in free cash flow, which turned positive at ₹19,567.6 million from a negative position the previous year. Operating cash flow has increased significantly, leading to a favorable operating cash flow to net income ratio. The free cash flow to net income ratio has also improved, reflecting better cash management and profitability.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue320.25B317.24B290.02B248.55B234.55B247.75B
Gross Profit183.74B182.40B160.16B132.14B130.06B145.85B
EBITDA64.81B64.36B57.64B36.34B43.11B53.95B
Net Income33.91B34.86B31.73B19.27B26.48B53.35B
Balance Sheet
Total Assets0.00497.85B450.72B398.90B339.22B338.54B
Cash, Cash Equivalents and Short-Term Investments82.36B82.36B63.25B62.24B45.58B56.21B
Total Debt0.0082.63B66.48B52.86B32.79B53.39B
Total Liabilities-326.47B171.38B152.21B130.38B93.48B119.25B
Stockholders Equity326.47B326.53B298.43B268.40B245.76B219.30B
Cash Flow
Free Cash Flow0.0019.57B-11.27B-3.34B23.12B14.55B
Operating Cash Flow0.0039.25B24.35B23.87B50.16B33.29B
Investing Cash Flow0.00-18.76B-42.56B-39.78B-32.12B5.99B
Financing Cash Flow0.001.20B8.00B18.14B-29.69B-13.65B

Aurobindo Pharma Ltd Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1112.70
Price Trends
50DMA
1083.07
Positive
100DMA
1101.51
Positive
200DMA
1130.41
Negative
Market Momentum
MACD
3.09
Positive
RSI
55.72
Neutral
STOCH
47.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AUROPHARMA, the sentiment is Positive. The current price of 1112.7 is above the 20-day moving average (MA) of 1101.94, above the 50-day MA of 1083.07, and below the 200-day MA of 1130.41, indicating a neutral trend. The MACD of 3.09 indicates Positive momentum. The RSI at 55.72 is Neutral, neither overbought nor oversold. The STOCH value of 47.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AUROPHARMA.

Aurobindo Pharma Ltd Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
₹630.26B18.580.36%7.76%-2.84%
₹663.10B29.020.83%4.49%11.22%
₹877.48B23.700.61%12.40%63.16%
₹993.45B21.731.10%14.52%9.46%
₹485.71B95.390.13%25.83%421.20%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
₹522.88B69.690.14%10.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,112.70
-278.08
-19.99%
IN:ALKEM
Alkem Laboratories Ltd.
5,535.70
-193.52
-3.38%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
1,843.25
154.10
9.12%
IN:LAURUSLABS
Laurus Labs Ltd.
961.50
470.67
95.89%
IN:LUPIN
Lupin Limited
1,921.10
-251.65
-11.58%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,001.80
11.30
1.14%

Aurobindo Pharma Ltd Corporate Events

Aurobindo Pharma Expands into Chilean Market with New Subsidiary
Oct 23, 2025

Aurobindo Pharma Ltd has announced the incorporation of a new wholly owned subsidiary, Aurobindo Pharma Chile SpA, through its existing subsidiary Helix Healthcare B.V. This strategic move aims to expand Aurobindo’s pharmaceutical business into the Chilean market, enhancing its global footprint. The incorporation involves a 100% cash subscription to the share capital, with no governmental or regulatory approvals required, indicating a smooth entry into the Chilean market.

Aurobindo Pharma Expands into Chile with New Subsidiary
Oct 23, 2025

Aurobindo Pharma Ltd has announced the incorporation of a new wholly owned subsidiary, Eugia Pharma Chile SpA, in Chile through its stepdown subsidiary, Eugia Pharma B.V. This strategic move aims to expand Aurobindo’s pharmaceutical business in the Chilean market, enhancing its international footprint and potentially increasing its market share in the region. The incorporation involves a 100% cash subscription to the share capital, with no governmental or regulatory approvals required, indicating a streamlined expansion process.

Aurobindo Pharma Expands into Malaysia with New Subsidiary
Sep 17, 2025

Aurobindo Pharma Ltd has announced the incorporation of a new wholly owned subsidiary, Aurobindo Pharma (Malaysia) SDN. BHD., through its subsidiary Helix Healthcare B.V. This strategic move aims to expand the company’s pharmaceutical products business in Malaysia, enhancing its market footprint in the region. The new entity is fully owned by Aurobindo Pharma, with an initial investment of RM 400,000, and is expected to bolster the company’s operations and competitive positioning in the Southeast Asian pharmaceutical market.

Aurobindo Pharma’s Apitoria Unit Completes US FDA Inspection with Procedural Observations
Aug 29, 2025

Aurobindo Pharma Limited announced the completion of a US FDA inspection at Unit-I of its wholly owned subsidiary, Apitoria Pharma Private Limited, located in Telangana, India. The inspection concluded with a ‘Form 483’ issued containing five procedural observations, but no data integrity issues were found. The company stated that these observations will not impact its financials or operations, reaffirming its commitment to maintaining high-quality manufacturing standards.

Aurobindo Pharma to Engage in Virtual Investor Conference
Aug 12, 2025

Aurobindo Pharma Ltd has announced its participation in an upcoming virtual investor conference organized by Centrum Broking on August 20, 2025. This engagement reflects the company’s ongoing efforts to maintain transparency with stakeholders and investors, although no unpublished price-sensitive information will be disclosed during the meeting.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 18, 2025